Cullinan Therapeutics, Inc.
Zipalertinib
EGFR ex20ins NSCLC
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for Zipalertinib in EGFR ex20ins NSCLC are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Taiho expects to obtain top-line results by the end of 2026.”